Age-Related Macular Degeneration: Understanding AMD

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among adults over 50 in the United States, affecting approximately 19.8 million Americans aged 40 and older (National Eye Institute, 2024). That number is projected to grow substantially as the population ages — the NEI estimates that by 2050, AMD cases could nearly double. The disease attacks the macula, a small but extraordinarily important patch of tissue at the center of the retina responsible for sharp, straight-ahead vision. Reading, driving, recognizing faces — all of it depends on a healthy macula roughly 5 millimeters across.

What Happens in the Macula

The retina functions something like the film in an analog camera, converting light into neural signals. The macula sits at the very center, densely packed with photoreceptor cells called cones. When AMD develops, the supporting tissue beneath these photoreceptors — the retinal pigment epithelium (RPE) and Bruch's membrane — begins to deteriorate. Waste products accumulate, nutrient transport falters, and the delicate architecture that keeps those cone cells alive starts to break down.

The earliest clinical sign is often the appearance of drusen, small yellowish deposits beneath the retina visible during a dilated eye exam. A handful of small drusen can be entirely normal with aging. The trouble begins when drusen grow larger (exceeding 63 micrometers, roughly the width of a human hair) or become more abundant. At that point, the risk of progression to vision-threatening AMD increases significantly (American Academy of Ophthalmology).

Dry AMD vs. Wet AMD

AMD exists in two forms, and the distinction matters enormously for both prognosis and treatment.

Dry (Atrophic) AMD

Dry AMD accounts for approximately 85–90% of all AMD cases (National Eye Institute). It progresses through three stages — early, intermediate, and late (geographic atrophy). In geographic atrophy, patches of the RPE and overlying photoreceptors die off entirely, leaving well-defined zones of lost retinal function. Vision loss tends to be gradual, sometimes spanning years. Until 2023, no FDA-approved treatment existed for geographic atrophy. That changed with the approval of pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), both targeting components of the complement system — part of the immune cascade implicated in RPE destruction (FDA, 2023).

Wet (Neovascular) AMD

Wet AMD is less common but far more aggressive. Abnormal blood vessels grow beneath the retina through a process called choroidal neovascularization (CNV). These vessels are fragile and prone to leaking fluid and blood, which can distort and destroy central vision in weeks or months rather than years. Anti-vascular endothelial growth factor (anti-VEGF) injections — drugs such as ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo) — have transformed outcomes for wet AMD since the mid-2000s, stabilizing or improving vision in a substantial majority of treated patients (NEI).

Risk Factors

Age is the dominant risk factor — prevalence rises sharply after age 60 and again after 75. But biology and behavior both play roles:

• Smoking roughly doubles the risk of AMD. It remains the single most modifiable risk factor (CDC).
• Genetics contribute substantially. Variants in the complement factor H (CFH) gene and the ARMS2/HTRA1 locus on chromosome 10 account for a large share of genetic risk. Having a first-degree relative with AMD increases risk three- to fourfold.
• Race and ethnicity influence prevalence; AMD is more common among non-Hispanic white populations than among Black or Hispanic populations, though it occurs across all groups.
• Cardiovascular factors — hypertension, obesity, and high dietary saturated fat intake — have been associated with elevated AMD risk in large epidemiological studies, including the Beaver Dam Eye Study conducted by the University of Wisconsin.

The AREDS Studies

Two landmark randomized controlled trials — the Age-Related Eye Disease Studies (AREDS and AREDS2) — conducted by the National Eye Institute established that a specific combination of nutritional supplements can slow progression from intermediate to advanced AMD by about 25% over five years. The AREDS2 formula, which replaced beta-carotene with lutein (10 mg) and zeaxanthin (2 mg) to avoid increased lung cancer risk in smokers, is the current standard recommendation (NEI AREDS2 FAQ). These supplements do not prevent AMD from developing in the first place, nor do they benefit early-stage disease — a nuance frequently lost in consumer marketing.

Detection and Monitoring

Because early and intermediate AMD can be entirely asymptomatic, the American Academy of Ophthalmology recommends baseline comprehensive dilated eye exams at age 40, with periodic follow-up based on risk factors and findings (AAO). For individuals already diagnosed with intermediate or advanced AMD in one eye, home monitoring with an Amsler grid — a simple pattern of horizontal and vertical lines — can help detect new distortion that might signal conversion to wet AMD. Optical coherence tomography (OCT), which generates cross-sectional images of the retina at micrometer-level resolution, has become indispensable in both diagnosis and treatment monitoring.

Living with AMD

AMD does not cause total blindness. Peripheral vision remains intact even in advanced cases. Low-vision rehabilitation — including magnifying devices, large-print materials, screen readers, and eccentric viewing training — can make a meaningful difference in daily function and independence. The Academy's EyeSmart program and organizations like the Foundation Fighting Blindness provide patient-facing resources grounded in clinical evidence.

The landscape of AMD treatment is shifting faster than at any point in the past two decades. Geographic atrophy now has approved therapies. Gene therapy trials are underway. Extended-durability anti-VEGF agents are reducing injection burden. For a disease once considered largely untreatable, the trajectory is worth paying attention to.

Frequently Asked Questions

Can AMD be reversed?

Vision lost to geographic atrophy (advanced dry AMD) cannot be restored with existing therapies. In wet AMD, anti-VEGF injections can sometimes recover vision that was recently lost due to fluid accumulation, but long-standing damage to photoreceptors is irreversible.

At what age should screening for AMD begin?

The American Academy of Ophthalmology recommends a baseline dilated eye exam at age 40 for all adults, with more frequent exams after age 65 or earlier if risk factors such as smoking or family history are present (AAO).

Are AREDS2 supplements helpful for everyone with AMD?

No. The AREDS2 formula has demonstrated benefit specifically for individuals with intermediate AMD or advanced AMD in one eye. Those with early AMD or no AMD do not gain measurable protection from these supplements (NEI).

References

• National Eye Institute — Age-Related Macular Degeneration
• American Academy of Ophthalmology — AMD Overview
• FDA — Approval of First Treatment for Geographic Atrophy (2023)
• NEI — AREDS2 Supplements FAQ
• CDC — Age-Related Macular Degeneration Data
• AAO — Eye Exam Recommendations

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)